Review studies that examined the efficacy and safety of Xultophy® 100/3.6, a combination of insulin degludec and liraglutide. The links below will take you to the abstracts of these clinical trials on PubMed.gov, the website of the US National Library of Medicine and National Institutes of Health.
Xultophy® 100/3.6 clinical studies
Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin; DUAL VII Randomized Control Trial
A 26-week, randomized, open-label trial in adult patients with type 2 diabetes inadequately controlled on insulin glargine U-100 (20-50 units) + metformin (n=506).1
Billings LK, Doshi A, Gouet D, et al. Diabetes Care. 2018;41(5):1009-1016.
Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial
A 26-week, randomized, open-label trial in adult patients with type 2 diabetes inadequately controlled on insulin glargine U-100 (20-50 units) + metformin (n=557).2,3
Lingvay I, Manghi FP, García-Hernández P, et al; for the DUAL V Investigators. JAMA. 2016;315(9):898-907.
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial
A phase 3B, multicenter, international, randomized, double-blind, placebo-controlled study to assess the cardiovascular safety of liraglutide for patients with type 2 diabetes at high risk for cardiovascular disease (N=9340).4
Marso SP, Poulter NR, Nissen SE, et al. Design of the liraglutide effect and action in diabetes: evaluation or cardiovascular outcomes results (LEADER) trial. Am Heart J. 2013;166(5):823-830.
Efficacy and safety of degludec versus glargine in type 2 diabetes
A multicenter, multinational, randomized, double-blind, active-controlled, treat-to-target, event-driven trial on adult patients with inadequately controlled T2D and ASCVD (n=7637).5
Marso SP, McGuire DK, Zinman B, et al. N Engl J Med. 2017;377(8):723-732.